<i>In Vitro</i> Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens

Abstract

We tested the <i>in vitro</i> activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 <i>Burkholderia</i>, <i>Achromobacter</i>, <i>Stenotrophomonas</i>, and <i>Pandoraea</i> strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis. Among the β-lactam-β-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against <i>Burkholderia</i> and <i>Achromobacter</i>, including multidrug-resistant and extensively-drug-resistant strains. None of the newer β-lactam-β-lactamase combination drugs showed increased activity compared to that of the older agents against <i>Stenotrophomonas maltophilia</i> or <i>Pandoraea</i> spp.